Vaccines for cancer prevention: exploring opportunities and navigating challenges
Michele Graciotti1,2, Lana E Kandalaft3,4,5,6
1Center of Experimental Therapeutics, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Abstract:
Improved understanding of cancer immunology has gradually brought increasing attention towards cancer-preventive vaccines as an important tool in the fight against cancer. The aim of this approach is to reduce cancer occurrence by inducing a specific immune response targeting tumours at an early stage before they can fully develop. The great advantage of preventive cancer vaccines lies in the potential to harness a less-compromised immune system in vaccine recipients before their immune responses become affected by the advanced status of the disease itself or by aggressive treatments such as chemotherapy. Successful implementation of immunoprevention against oncogenic viruses such as hepatitis B and papillomavirus has led to a dramatic decrease in virally induced cancers. Extending this approach to other cancers holds great promise but remains a major challenge. Here, we provide a comprehensive review of preclinical evidence supporting this approach, encouraging results from pioneering clinical studies as well as a discussion on the key aspects and open questions to address in order to design potent prophylactic cancer vaccines in the near future.
Insights
Cancer-preventive vaccines harness the immune system to target early-stage tumors, offering a promising strategy to reduce cancer incidence. This review explores preclinical and clinical evidence for prophylactic cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Advances in cancer immunology highlight the potential of cancer-preventive vaccines.
- Prophylactic vaccines aim to induce immune responses against early-stage tumors, before disease progression or treatment interference.
- Successful viral cancer prevention (e.g., Hepatitis B, HPV) provides a model for broader cancer immunoprevention.
Purpose of the Study:
- To review preclinical evidence supporting cancer-preventive vaccines.
- To discuss encouraging results from early clinical studies.
- To identify key challenges and future directions for designing effective prophylactic cancer vaccines.
Main Methods:
- Comprehensive literature review of preclinical studies.
- Analysis of data from pioneering clinical trials.
- Discussion of immunological principles and vaccinology challenges.
Main Results:
- Significant preclinical data support the feasibility of cancer-preventive vaccines.
- Early clinical studies show promising, encouraging results.
- The potential to leverage a less-compromised immune system is a key advantage.
Conclusions:
- Cancer-preventive vaccines represent a promising strategy to reduce cancer occurrence.
- Further research and development are needed to overcome challenges in designing potent prophylactic cancer vaccines.
- Addressing key aspects and open questions is crucial for future vaccine design.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Prevention
Some...
Vaccinations
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
